Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
MC

Mark Stuart Chambers — 73 Patents

Merck: 44 patents #141 of 9,382Top 2%
Genentech: 8 patents #386 of 2,392Top 20%
Johnson & Johnson: 7 patents #1,421 of 7,810Top 20%
GNGalapagos Nv: 3 patents #70 of 177Top 40%
CFChdi Foundation: 2 patents #46 of 89Top 55%
MDMerk Sharp & Dohme: 1 patents #1 of 28Top 4%
NTNeumora Therapeutics: 1 patents #25 of 36Top 70%
OCOno Pharmaceutical Co.: 1 patents #329 of 559Top 60%
Astrazeneca Ab: 1 patents #1,022 of 1,971Top 55%
ASAlmirall, S.A.: 1 patents #37 of 81Top 50%
BTBlackthorn Therapeutics: 1 patents #19 of 24Top 80%
Saffron Walden, GB: #2 of 225 inventorsTop 1%
Overall (All Time): #26,958 of 4,157,543Top 1%
73 Patents All Time
Mark Stuart Chambers has been granted 73 US patents while listed as an inventor at Merck. The first was granted in 1993 and the most recent in November 2025. Mark Stuart Chambers ranks #26,958 of 4,157,543 US inventors in our database (top 0.65%). Patent records list Mark Stuart Chambers in Saffron Walden, GB.

Patents per Year

Patents granted per year, 1993 to 2025Bar chart with a peak of 6 patents in 1999.peak 61993: 2 patents19931994: 2 patents1995: 2 patents1996: 2 patents19961997: 5 patents1998: 4 patents1999: 6 patents19992000: 4 patents2001: 1 patents2002: 3 patents20022003: 1 patents2004: 1 patents2005: 3 patents20052006: 5 patents2007: 2 patents2009: 3 patents20092011: 3 patents2012: 5 patents2013: 1 patents20132014: 5 patents2015: 3 patents2018: 2 patents20182019: 1 patents2020: 1 patents2022: 1 patents20222023: 1 patents2024: 1 patents2025: 3 patents2025

Issued Patents All Time

Showing 1–25 of 73 patents

Patent #TitleCo-InventorsDateApprox Value ⓘ
12465603 Phthalazinone based modulators for the treatment of disease Nadia Ahmad, Christopher Rennie, William Rameshchandra Krishna Esmieu, Toby Jonathan Blench, Susan Mary Cramp +3 more 2025-11-11
12281116 HTT modulators for treating Huntington's disease Longbin Liu, Celia Dominguez, Nikolay V. Plotnikov, Alan Findlay Haughan, Andrew J. Stott +6 more 2025-04-22
12202816 Compounds as NADPH oxidase inhibitors Peter J. Machin, Alastair James Hodges, Andrew Sharpe, Grant Wishart, Benjamin Perry +2 more 2025-01-21
12152038 Vasopressin receptor antagonists and products and methods related thereto Robert M. Jones, Mariangela Urbano, Gary E. L. Brandt, David Hardick, Chris Knight +2 more 2024-11-26 $25,454,000
11806346 HTT modulators for treating Huntington's disease Celia Dominguez, Elizabeth M. Doherty, Longbin Liu, Matthew Lee, Karine Fabienne Malagu +7 more 2023-11-07
11248001 PCSK9 inhibitors and methods of use thereof Michael H. Serrano-Wu, Erica Goldsmith, Jason Tierney, Karamjit Singh Jandu, David W. Clark +1 more 2022-02-15 $120,757,000
10538530 Vasopressin receptor antagonists and products and methods related thereto Robert M. Jones, Mariangela Urbano, Gary E. L. Brandt, David Hardick, Chris Knight +2 more 2020-01-21
10214509 Amino-substituted heterocyclic derivatives as sodium channel inhibitors James E. Duffy, Alastair Rae, James Daniel OSBORNE, Isabelle Anne LEMASSON, Michael Daniel Goldsmith +2 more 2019-02-26
10130619 Amido thiadiazole derivatives as NADPH oxidase inhibitors Peter J. Machin, Andrew Sharpe, Christopher James Lock, Alastair James Hodges, VIVIENNE ALLEN +1 more 2018-11-20
10016439 Fused imidazole compounds Tetsuji Saito, Masato Higashino, Soichi KAWAHARADA, Arwel Lewis, Alastair Rae +2 more 2018-07-10
9212173 Pyrazole aminopyrimidine derivatives as LRRK2 modulators Charles Baker-Glenn, Daniel J. Burdick, Bryan Chan, Huifen Chen, Anthony A. Estrada +1 more 2015-12-15
9145402 Aminopyrimidine derivatives as LRRK2 modulators Charles Baker-Glenn, Bryan Chan, Anthony A. Estrada, Daniel Shore, Zachary K. Sweeney +1 more 2015-09-29
9006237 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases Martin James Inglis Andrews, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Gregory Bar, Kim Louise Hirst +2 more 2015-04-14 $52,905,000
8815882 Pyrazole aminopyrimidine derivatives as LRRK2 modulators Charles Baker-Glenn, Daniel J. Burdick, Bryan Chan, Huifen Chen, Anthony A. Estrada +1 more 2014-08-26
8809331 Aminopyrimidine derivatives as LRRK2 modulators Charles Baker-Glenn, Daniel J. Burdick, Bryan Chan, Huifen Chen, Anthony A. Estrada +5 more 2014-08-19
8802674 Aminopyrimidine derivatives as LRRK2 modulators Charles Baker-Glenn, Daniel J. Burdick, Bryan Chan, Huifen Chen, Anthony A. Estrada +5 more 2014-08-12
8796296 Aminopyrimidine derivatives as LRRK2 modulators Charles Baker-Glenn, Bryan Chan, Anthony A. Estrada, Zachary K. Sweeney 2014-08-05
8791130 Aminopyrimidine derivatives as LRRK2 modulators Charles Baker-Glenn, Bryan Chan, Anthony A. Estrada, Zachary K. Sweeney 2014-07-29
8354420 Aminopyrimidine derivatives as LRRK2 inhibitors Charles Baker-Glenn, Daniel J. Burdick, Bryan Chan, Huifen Chen, Anthony A. Estrada +5 more 2013-01-15
8178530 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt +6 more 2012-05-15 $162,458,000
8173656 Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt +6 more 2012-05-08 $104,726,000
8148369 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases Martin James Inglis Andrews, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Gregory Bar, Kim Louise Hirst +2 more 2012-04-03 $38,531,000
8138193 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases Martin James Inglis Andrews, Wolfgang Schmidt, Gregory Bar 2012-03-20 $58,490,000
8133895 Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases Martin James Inglis Andrews, Wolfgang Schmidt, Gregory Bar 2012-03-13 $84,129,000
8012983 Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases Martin James Inglis Andrews, Hervé Van De Poël, Gregory Bar 2011-09-06